Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Stetler-Stevenson Website

William G. Stetler-Stevenson, M.D., Ph.D.

Selected Publications

1)  Han H, Bourboulia D, Jensen-Taubman S, Isaac B, Wei B, Stetler-Stevenson WG.
An endogenous inhibitor of angiogenesis inversely correlates with side population phenotype and function in human lung cancer cells.
Oncogene. 33: 1198-206, 2014.
2)  Kim SH, Cho YR, Kim HJ, Oh JS, Ahn EK, Ko HJ, Hwang BJ, Lee SJ, Cho Y, Kim YK, Stetler-Stevenson WG, Seo DW.
Antagonism of VEGF-A-induced increase in vascular permeability by an integrin a3ß1-Shp-1-cAMP/PKA pathway.
Blood. 120: 4892-902, 2012.
3)  Seo DW, Li H, Guedez L, Wingfield PT, Diaz T, Salloum R, Wei BY, Stetler-Stevenson WG.
TIMP-2 Mediated Inhibition of Angiogenesis: An MMP-Independnet Mechanism.
Cell. 114: 171-180, 2003.
4)  Giannelli G, Falk-Marzillier J, Schiraldi O, Stetler-Stevenson WG, Quaranta V.
Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5.
Science. 277: 225-8, 1997.
5)  Stetler-Stevenson WG, Aznavoorian S, Liotta LA.
Tumor cell interactions with the extracellular matrix during invasion and metastasis.
Annu. Rev. Cell Biol. 9: 541-73, 1993.
6)  Mollapour M, Bourboulia D, Beebe K, Woodford MR, Polier S, Hoang A, Chelluri R, Li Y, Guo A, Lee MJ, Fotooh-Abadi E, Khan S, Prince T, Miyajima N, Yoshida S, Tsutsumi S, Xu W, Panaretou B, Stetler-Stevenson WG, Bratslavsky G, Trepel JB, Prodromou C, Neckers L.
Asymmetric Hsp90 N domain SUMOylation recruits Aha1 and ATP-competitive inhibitors.
Mol. Cell. 53: 317-29, 2014.
7)  Shuman Moss LA, Jensen-Taubman S, Rubinstein D, Viole G, Stetler-Stevenson WG.
Dietary intake of a plant phospholipid/lipid conjugate reduces lung cancer growth and tumor angiogenesis.
Carcinogenesis. [Epub ahead of print], 2014.
8)  Stetler-Stevenson WG, Gavil NV.
Normalization of the tumor microenvironment: evidence for tissue inhibitor of metalloproteinase-2 as a cancer therapeutic.
Connect. Tissue Res. 55: 13-9, 2014.
9)  Shuman Moss LA, Stetler-Stevenson WG.
Influence of Stromal Components on Lung Cancer Carcinogenesis.
J Carcinog Mutagen. 13, 2013.
10)  Fang C, Avis I, Bianco C, Held N, Morris J, Ylaya K, Hewitt SM, Aplin AC, Nicosia RF, Fung LA, Lewis JD, Stetler-Stevenson WG, Salomon DS, Cuttitta F.
SCNH2 is a novel apelinergic family member acting as a potent mitogenic and chemotactic factor for both endothelial and epithelial cells.
Open J Clin Diagn. 3: 37-51, 2013.
11)  Bourboulia D, Han H, Jensen-Taubman S, Gavil N, Isaac B, Wei B, Neckers L, Stetler-Stevenson WG.
TIMP-2 modulates cancer cell transcriptional profile and enhances E-cadherin/beta-catenin complex expression in A549 lung cancer cells.
Oncotarget. 4: 163-73, 2013.
12)  Bourboulia D, Han H, Jensen-Taubman S, Gavil N, Isaac B, Wei B, Neckers L, Stetler-Stevenson WG.
TIMP-2 modulates cancer cell transcriptional profile and enhances E-cadherin/beta-catenin complex expression in A549 lung cancer cells.
Oncotarget. 4: 166-76, 2013.
13)  Adamson A, Ghoreschi K, Rittler M, Chen Q, Sun HW, Vahedi G, Kanno Y, Stetler-Stevenson WG, O'Shea JJ, Laurence A.
Tissue inhibitor of metalloproteinase 1 is preferentially expressed in Th1 and th17 T-helper cell subsets and is a direct stat target gene.
PLoS ONE. 8: e59367, 2013.
14)  Stetler-Stevenson W, Bourboulia D, Guedex L, Jensen-Taubman S.
Anti-tumoral Properties of Endogenous Angiogenesis Inhibitors: A Case for Continued TIMP-2 Preclinical Development.
Curr. Angiogenesis. 1: 148-56, 2012.
15)  Iwai A, Bourboulia D, Mollapour M, Jensen-Taubman S, Lee S, Donnelly AC, Yoshida S, Miyajima N, Tsutsumi S, Smith AK, Sun D, Wu X, Blagg BS, Trepel JB, Stetler-Stevenson WG, Neckers L.
Combined inhibition of Wee1 and Hsp90 activates intrinsic apoptosis in cancer cells.
Cell Cycle. 11: 3649-55, 2012.
16)  Gonçalves AN, Meschiari CA, Stetler-Stevenson WG, Nonato MC, Alves CP, Espreafico EM, Gerlach RF.
Expression of soluble and functional full-length human matrix metalloproteinase-2 in Escherichia coli.
J. Biotechnol. 157: 20-4, 2012.
17)  Shuman Moss LA, Jensen-Taubman S, Stetler-Stevenson WG.
Matrix metalloproteinases: changing roles in tumor progression and metastasis.
Am. J. Pathol. 181: 1895-9, 2012.
18)  Bourboulia D, Jensen-Taubman S, Stetler-Stevenson W.
TIMP-2 An Endogenous Angiogenesis Inhibitor with Distinct Antitumoral Properties.
Treat. Strategies Hematol. 2: 31-35, 2012.
19)  Guedez L, Jensen-Taubman S, Bourboulia D, Kwityn CJ, Wei B, Caterina J, Stetler-Stevenson WG.
TIMP-2 Targets Tumor-associated Myeloid Suppressor Cells With Effects in Cancer Immune Dysfunction and Angiogenesis.
J. Immunother. 35: 502-12, 2012.
20)  Seo D, Saxinger WC, Guedez L, Cantelmo AR, Albini A, Stetler-Stevenson WG.
An integrin-binding N-terminal peptide region of TIMP-2 retains potent angio-inhibitory and anti-tumorigenic activity in vivo.
Peptides. 32: 1840-8, 2011.
21)  Bourboulia D, Jensen-Taubman S, Rittler MR, Han HY, Chatterjee T, Wei B, Stetler-Stevenson WG.
Endogenous angiogenesis inhibitor blocks tumor growth via direct and indirect effects on tumor microenvironment.
Am. J. Pathol. 179: 2589-600, 2011.
22)  Bourboulia D, Stetler-Stevenson WG.
Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion.
Semin Cancer Biol. 20: 161-168, 2010.
23)  Mollapour M, Tsutsumi S, Donnelly AC, Beebe K, Tokita MJ, Lee MJ, Lee S, Morra G, Bourboulia D, Scroggins BT, Colombo G, Blagg BS, Panaretou B, Stetler-Stevenson WG, Trepel JB, Piper PW, Prodromou C, Pearl LH, Neckers L.
Swe1Wee1-dependent tyrosine phosphorylation of Hsp90 regulates distinct facets of chaperone function.
Mol. Cell. 37: 333-43, 2010.
24)  Metaferia BB, Rittler M, Gheeya JS, Lee A, Hempel H, Plaza A, Stetler-Stevenson WG, Bewley CA, Khan J.
Synthesis of novel cyclic NGR/RGD peptide analogs via on resin click chemistry.
Bioorg. Med. Chem. Lett. 20: 7337-40, 2010.
25)  Guedez L, Stetler-Stevenson WG.
The prognostic value of TIMP-1 in multiple myeloma.
Leuk. Res. 34: 576-7, 2010.
26)  Lee SJ, Tsang PS, Diaz TM, Wei BY, Stetler-Stevenson WG.
TIMP-2 modulates VEGFR-2 phosphorylation and enhances phosphodiesterase activity in endothelial cells.
Lab. Invest. 90: 374-82, 2010.
27)  Alper O, Stetler-Stevenson WG, Harris LN, Leitner WW, Ozdemirli M, Hartmann D, Raffeld M, Abu-Asab M, Byers S, Zhuang Z, Oldfield EH, Tong Y, Bergmann-Leitner E, Criss WE, Nagasaki K, Mok SC, Cramer DW, Karaveli FS, Goldbach-Mansky R, Leo P, Stromberg K, Weil RJ.
Novel anti-filamin-A antibody detects a secreted variant of filamin-A in plasma from patients with breast carcinoma and high-grade astrocytoma.
Cancer Sci. 100: 1748-56, 2009.
28)  Sun J, Stetler-Stevenson WG.
Overexpression of tissue inhibitors of metalloproteinase 2 up-regulates NF-kappaB activity in melanoma cells.
J Mol Signal. 4: 4, 2009.
29)  Glassberg MK, Elliot SJ, Fritz J, Catanuto P, Potier M, Donahue R, Stetler-Stevenson W, Karl M.
Activation of the estrogen receptor contributes to the progression of pulmonary lymphangioleiomyomatosis via matrix metalloproteinase-induced cell invasiveness.
J. Clin. Endocrinol. Metab. 93: 1625-33, 2008.
30)  Lee H, Lim C, Lee J, Kim N, Bang S, Lee H, Min B, Park G, Noda M, Stetler-Stevenson WG, Oh J.
TGF-beta signaling preserves RECK expression in activated pancreatic stellate cells.
J. Cell. Biochem. 104: 1065-74, 2008.
31)  Stetler-Stevenson WG.
The tumor microenvironment: regulation by MMP-independent effects of tissue inhibitor of metalloproteinases-2.
Cancer Metastasis Rev. 27: 57-66, 2008.
32)  Seo D, Kim SH, Eom S, Yoon HJ, Cho Y, Kim P, Kim YK, Han J, Diaz T, Wei B, Stetler-Stevenson WG.
TIMP-2 disrupts FGF-2-induced downstream signaling pathways.
Microvasc. Res. 76: 145-51, 2008.
33)  Kim Y, Seo D, Kong S, Lee J, Lee E, Stetler-Stevenson M, Stetler-Stevenson WG.
TIMP1 induces CD44 expression and the activation and nuclear translocation of SHP1 during the late centrocyte/post-germinal center B cell differentiation.
Cancer Lett. 269: 37-45, 2008.
34)  Stetler-Stevenson WG.
Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase-independent biological activities.
Sci Signal. 1: re6, 2008.
35)  Haviernik P, Diaz MT, Haviernikova E, Tse W, Stetler-Stevenson WG, Bunting KD.
Hematopoiesis in mice is extremely resilient to wide variation in TIMP/MMP balance.
Blood Cells Mol. Dis. 2007.
36)  Horak CE, Lee JH, Elkahloun AG, Boissan M, Dumont S, Maga TK, Arnaud-Dabernat S, Palmieri D, Stetler-Stevenson WG, Lacombe ML, Meltzer PS, Steeg PS.
Nm23-H1 suppresses tumor cell motility by down-regulating the lysophosphatidic acid receptor EDG2.
Cancer Res. 67: 7238-46, 2007.
37)  Khakoo AY, Pati S, Anderson SA, Reid W, Elshal MF, Rovira II, Nguyen AT, Malide D, Combs CA, Hall G, Zhang J, Raffeld M, Rogers TB, Stetler-Stevenson W, Frank JA, Reitz M, Finkel T.
Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi"s sarcoma.
J. Exp. Med. 203: 1235-47, 2006.
38)  Seo DW, Li H, Qu CK, Oh J, Kim YS, Diaz T, Wei B, Han JW, Stetler-Stevenson WG.
Shp-1 mediates the antiproliferative activity of tissue inhibitor of metalloproteinase-2 in human microvascular endothelial cells.
J. Biol. Chem. 281: 3711-21, 2006.
39)  Chang H, Lee J, Poo H, Noda M, Diaz T, Wei B, Stetler-Stevenson WG, Oh J.
TIMP-2 promotes cell spreading and adhesion via upregulation of Rap1 signaling.
Biochem. Biophys. Res. Commun. 345: 1201-6, 2006.
40)  Oh J, Diaz T, Wei B, Chang H, Noda M, Stetler-Stevenson WG.
TIMP-2 upregulates RECK expression via dephosphorylation of paxillin tyrosine residues 31 and 118.
Oncogene. 25: 4230-4, 2006.
41)  Stuelten CH, DaCosta Byfield S, Arany PR, Karpova TS, Stetler-Stevenson WG, Roberts AB.
Breast cancer cells induce stromal fibroblasts to express MMP-9 via secretion of TNF-alpha and TGF-beta.
J Cell Sci. 118: 2143-53, 2005.
42)  Wang T, Ward Y, Tian L, Lake R, Guedez L, Stetler-Stevenson WG, Kelly K.
CD97, an adhesion receptor on inflammatory cells, stimulates angiogenesis through binding integrin counterreceptors on endothelial cells.
Blood. 105: 2836-44, 2005.
43)  Larsen MB, Stephens RW, Brünner N, Nielsen HJ, Engelholm LH, Christensen IJ, Stetler-Stevenson WG, Høyer-Hansen G.
Quantification of tissue inhibitor of metalloproteinases 2 in plasma from healthy donors and cancer patients.
Scand J Immunol. 61: 449-60, 2005.
44)  Bianco C, Strizzi L, Ebert A, Chang C, Rehman A, Normanno N, Guedez L, Salloum R, Ginsburg E, Sun Y, Khan N, Hirota M, Wallace-Jones B, Wechselberger C, Vonderhaar BK, Tosato G, Stetler-Stevenson WG, Sanicola M, Salomon DS.
Role of human cripto-1 in tumor angiogenesis.
J. Natl. Cancer Inst. 97: 132-41, 2005.
45)  Stetler-Stevenson WG, Seo DW.
TIMP-2: an endogenous inhibitor of angiogenesis.
Trends Mol Med. 11: 97-103, 2005.
46)  Guedez L, Martinez A, Zhao S, Vivero A, Pittaluga S, Stetler-Stevenson M, Raffeld M, Stetler-Stevenson WG.
Tissue inhibitor of metalloproteinase 1 (TIMP-1) promotes plasmablastic differentiation of a Burkitt lymphoma cell line: implications in the pathogenesis of plasmacytic/plasmablastic tumors.
Blood. 105: 1660-8, 2005.
47)  Martínez A, Oh HR, Unsworth EJ, Bregonzio C, Saavedra JM, Stetler-Stevenson WG, Cuttitta F.
Matrix metalloproteinase-2 cleavage of adrenomedullin produces a vasoconstrictor out of a vasodilator.
Biochem J. 383: 413-8, 2004.
48)  Adair JC, Charlie J, Dencoff JE, Kaye JA, Quinn JF, Camicioli RM, Stetler-Stevenson WG, Rosenberg GA.
Measurement of gelatinase B (MMP-9) in the cerebrospinal fluid of patients with vascular dementia and Alzheimer disease.
Stroke. 35: e159-62, 2004.
49)  Feldman AL, Stetler-Stevenson WG, Costouros NG, Knezevic V, Baibakov G, Alexander HR, Lorang D, Hewitt SM, Seo DW, Miller MS, O'Connor S, Libutti SK.
Modulation of tumor-host interactions, angiogenesis, and tumor growth by tissue inhibitor of metalloproteinase 2 via a novel mechanism.
Cancer Res. 64: 4481-6, 2004.
50)  Tester AM, Waltham M, Oh SJ, Bae SN, Bills MM, Walker EC, Kern FG, Stetler-Stevenson WG, Lippman ME, Thompson EW.
Pro-matrix metalloproteinase-2 transfection increases orthotopic primary growth and experimental metastasis of MDA-MB-231 human breast cancer cells in nude mice.
Cancer Res. 64: 652-8, 2004.
51)  Martínez A, Zudaire E, Portal-Núñez S, Guédez L, Libutti SK, Stetler-Stevenson WG, Cuttitta F.
Proadrenomedullin NH2-terminal 20 peptide is a potent angiogenic factor, and its inhibition results in reduction of tumor growth.
Cancer Res. 64: 6489-94, 2004.
52)  Haviernik P, Lahoda C, Bradley HL, Hawley TS, Ramezani A, Hawley RG, Stetler-Stevenson M, Stetler-Stevenson WG, Bunting KD.
Tissue inhibitor of matrix metalloproteinase-1 overexpression in M1 myeloblasts impairs IL-6-induced differentiation.
Oncogene. 23: 9212-9, 2004.
53)  Oh J, Seo DW, Diaz T, Wei B, Ward Y, Ray JM, Morioka Y, Shi S, Kitayama H, Takahashi C, Noda M, Stetler-Stevenson WG.
Tissue inhibitors of metalloproteinase 2 inhibits endothelial cell migration through increased expression of RECK.
Cancer Res. 64: 9062-9, 2004.
54)  Kitsiou PV, Tzinia AK, Stetler-Stevenson WG, Michael AF, Fan WW, Zhou B, Tsilibary EC.
Glucose-induced changes in integrins and matrix-related functions in cultured human glomerular epithelial cells.
Am. J. Physiol. Renal Physiol. 284: F671-9, 2003.
55)  Guedez L, Rivera AM, Salloum R, Miller ML, Diegmueller JJ, Bungay PM, Stetler-Stevenson WG.
Quantitative Assessment of angiogenic responses by the directed in vivo angiogenesis assay.
Amer. J. Pathol. 162: 1431-1429, 2003.
56)  Matsui K, Takano Y, Yu ZX, Hi JE, Stetler-Stevenson WG, Travis WD, Ferrans VJ.
Immunohistochemical study of endothelin-1 and matrix metalloproteinases in plexogenic pulmonary arteriopathy.
Pathol. Res. Pract. 198: 403-12, 2002.
57)  Karamessinis PM, Tzinia AK, Kitsiou PV, Stetler-Stevenson WG, Michael AF, Fan WW, Zhou B, Margaritis LH, Tsilibary EC.
Proximal tubular epithelial cell integrins respond to high glucose by altered cell-matrix interactions and differentially regulate matrixin expression.
Lab. Invest. 82: 1081-93, 2002.
58)  Martínez A, Vos M, Guédez L, Kaur G, Chen Z, Garayoa M, Pío R, Moody T, Stetler-Stevenson WG, Kleinman HK, Cuttitta F.
The effects of adrenomedullin overexpression in breast tumor cells.
J. Natl. Cancer Inst. 94: 1226-1237, 2002.
59)  Seftor RE, Seftor EA, Koshikawa N, Meltzer PS, Gardner LM, Bilban M, Stetler-Stevenson WG, Quaranta V, Hendrix MJ.
Cooperative interactions of laminin 5 gamma 2 chain, matrix metalloproteinase-2, and membrane type-1 matrix metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma.
Cancer Res. 61: 6322-6327, 2001.
60)  Alper O , Bergmann-Leitner ES, Bennett TA, Hacker NF, Stromberg K, Stetler-Stevenson WG.
EGFR-Antisense In Ovarian Carcinoma Cells Reduces Integrin and Metalloproteinase-Mediated Attachment/Migration.
J. Natl. Cancer Inst. 93: 1375-1384, 2001.
61)  Vergani V, Garofalo A, Bani MR, Borsotti P, Parker MP, Drudis T, Mazzarol G, Viale G, Giavazzi R, Stetler-Stevenson WG, Taraboletti G.
Inhibition of matrix metalloproteinases by over-expression of tissue inhibitor of metalloproteinase-2 inhibits the growth of experimental hemangiomas.
Int. J. Cancer. 91: 241-7, 2001.
62)  Shankavaram UT, Lai WC, Netzel-Arnett S, Mangan PR, Ardans JA, Caterina N, Stetler-Stevenson WG, Birkedal-Hansen H, Wahl LM.
Monocyte membrane type 1-matrix metalloproteinase. Prostaglandin-dependent regulation and role in metalloproteinase-2 activation.
J. Biol. Chem. 276: 19027-32, 2001.
63)  Stetler-Stevenson WG, Yu AE.
Proteases in invasion: matrix metalloproteinases.
Semin. Cancer Biol. 11: 143-52, 2001.
64)  Stetler-Stevenson WG.
The role of matrix metalloproteinases in tumor invasion, metastasis, and angiogenesis.
Surg. Oncol. Clin. N. Am. 10: 383-92, x, 2001.
65)  Guedez L, Mansoor A, Birkedal-Hansen B, Lim MS, Fukushima P, Venzon D, Stetler-Stevenson WG, Stetler-Stevenson M.
TIMP-1 Regulation of IL-10 in B Cell Differentiation and Lymphomagenesis.
Blood. 97: 1796-1802, 2001.
66)  Guedez L, McMarlin AJ, Kingma DW, Bennett TA, Stetler-Stevenson M, Stetler-Stevenson WG.
Tissue Inhibitor of Metalloproteinases (TIMP)-1 Alters The Tumorigenicity of Burkitt's Lymphoma Via Divergent Effects on Tumor Growth and Angiogenesis.
Amer. J. Pathol. 158: 1207-1215, 2001.
67)  Hoegy SE, Oh HR, Corcoran ML, Stetler-Stevenson WG.
Tissue Inhibitor of Metalloproteinases-2 (TIMP-2) Suppresses TKR-Growth Factor Signaling Independent of Metalloproteinase Inhibition. J.
J. Biol. Chem. 276: 3203-3214, 2001.
68)  Hewitt RE, Brown KE, Corcoran M, Stetler-Stevenson WG.
Increased expression of tissue inhibitor of metalloproteinases type 1 (TIMP-1) in a more tumourigenic colon cancer cell line.
J. Pathol. 192: 455-9, 2000.
69)  Galateau-Salle FB, Luna RE, Horiba K, Sheppard MN, Hayashi T, Fleming MV, Colby TV, Bennett W, Harris CC, Stetler-Stevenson WG, Liotta L, Ferrans VJ, Travis WD.
Matrix metalloproteinases and tissue inhibitors of metalloproteinases in bronchial squamous preinvasive lesions.
Hum. Pathol. 31: 296-305, 2000.
70)  Lenz O, Elliot SJ, Stetler-Stevenson WG.
Matrix metalloproteinases in renal development and disease.
J. Am. Soc. Nephrol. 11: 574-81, 2000.
71)  Birkedal-Hansen B, Pavelic ZP, Gluckman JL, Stambrook P, Li YQ, Stetler-Stevenson WG.
MMP and TIMP gene expression in head and neck squamous cell carcinomas and adjacent tissues.
Oral diseases. 6: 376-82, 2000.
72)  Taraboletti G, Sonzogni L, Vergani V, Hosseini G, Ceruti R, Ghilardi C, Bastone A, Toschi E, Borsotti P, Scanziani E, Giavazzi R, Pepper MS, Stetler-Stevenson WG, Bani MR.
Posttranscriptional stimulation of endothelial cell matrix metalloproteinases 2 and 1 by endothelioma cells.
Exp. Cell Res. 258: 384-94, 2000.
73)  Hewitt RE, McMarlin A, Kleiner D, Wersto R, Martin P, Tsokos M, Stamp GW, Stetler-Stevenson WG, Tsoskas M.
Validation of a model of colon cancer progression.
J. Pathol. 192: 446-54, 2000.
74)  Wingfield PT, Sax JK, Stahl SJ, Kaufman J, Palmer I, Chung V, Corcoran ML, Kleiner DE, Stetler-Stevenson WG.
Biophysical and functional characterization of full-length, recombinant human tissue inhibitor of metalloproteinases-2 (TIMP-2) produced in Escherichia coli. Comparison of wild type and amino-terminal alanine appended variant with implications for the mechanism of TIMP functions.
J. Biol. Chem. 274: 21362-8, 1999.
75)  Giannelli G, Pozzi A, Stetler-Stevenson WG, Gardner HA, Quaranta V.
Expression of matrix metalloprotease-2-cleaved laminin-5 in breast remodeling stimulated by sex steroids.
Am. J. Pathol. 154: 1193-201, 1999.
76)  Marchetti C, Cornaglia I, Casasco A, Bernasconi G, Baciliero U, Stetler-Stevenson WG.
Immunolocalization of gelatinase-A (matrix metalloproteinase-2) in damaged human temporomandibular joint discs.
Arch. Oral Biol. 44: 297-304, 1999.
77)  Kleiner DE, Stetler-Stevenson WG.
Matrix metalloproteinases and metastasis.
Cancer Chemother. Pharmacol. 43 Suppl: S42-51, 1999.
78)  Stetler-Stevenson WG.
Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention.
J. Clin. Invest. 103: 1237-41, 1999.
79)  Elliot SJ, Striker LJ, Stetler-Stevenson WG, Jacot TA, Striker GE.
Pentosan polysulfate decreases proliferation and net extracellular matrix production in mouse mesangial cells.
J. Am. Soc. Nephrol. 10: 62-8, 1999.
80)  O'Reilly MS, Wiederschain D, Stetler-Stevenson WG, Folkman J, Moses MA.
Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance.
J. Biol. Chem. 274: 29568-71, 1999.
81)  Koochekpour S, Jeffers M, Wang PH, Gong C, Taylor GA, Roessler LM, Stearman R, Vasselli JR, Stetler-Stevenson WG, Kaelin WG, Linehan WM, Klausner RD, Gnarra JR, Vande Woude GF.
The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells.
Mol. Cell. Biol. 19: 5902-12, 1999.
82)  Lim MS, Guedez L, Stetler-Stevenson WG, Stetler-Stevenson M.
Tissue inhibitor of metalloproteinase-2 induces apoptosis in human T lymphocytes.
Ann. N. Y. Acad. Sci. 878: 522-3, 1999.
83)  Seftor RE, Seftor EA, De Larco JE, Kleiner DE, Leferson J, Stetler-Stevenson WG, McNamara TF, Golub LM, Hendrix MJ.
Chemically modified tetracyclines inhibit human melanoma cell invasion and metastasis.
Clin. Exp. Metastasis. 16: 217-25, 1998.
84)  Ota K, Stetler-Stevenson WG, Yang Q, Kumar A, Wada J, Kashihara N, Wallner EI, Kanwar YS.
Cloning of murine membrane-type-1-matrix metalloproteinase (MT-1-MMP) and its metanephric developmental regulation with respect to MMP-2 and its inhibitor.
Kidney Int. 54: 131-42, 1998.
85)  Segura AM, Luna RE, Horiba K, Stetler-Stevenson WG, McAllister HA, Willerson JT, Ferrans VJ.
Immunohistochemistry of matrix metalloproteinases and their inhibitors in thoracic aortic aneurysms and aortic valves of patients with Marfan"s syndrome.
Circulation. 98: II331-7; discussion II337-8, 1998.
86)  Guedez L, Stetler-Stevenson WG, Wolff L, Wang J, Fukushima P, Mansoor A, Stetler-Stevenson M.
In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1.
J. Clin. Invest. 102: 2002-10, 1998.
87)  Zuo J, Ferguson TA, Hernandez YJ, Stetler-Stevenson WG, Muir D.
Neuronal matrix metalloproteinase-2 degrades and inactivates a neurite-inhibiting chondroitin sulfate proteoglycan.
J. Neurosci. 18: 5203-11, 1998.
88)  Valente P, Fassina G, Melchiori A, Masiello L, Cilli M, Vacca A, Onisto M, Santi L, Stetler-Stevenson WG, Albini A.
TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis.
Int. J. Cancer. 75: 246-53, 1998.
89)  Stetler-Stevenson M, Mansoor A, Lim M, Fukushima P, Kehrl J, Marti G, Ptaszynski K, Wang J, Stetler-Stevenson WG.
Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in reactive and neoplastic lymphoid cells.
Blood. 89: 1708-15, 1997.
90)  Hayashi T, Fleming MV, Stetler-Stevenson WG, Liotta LA, Moss J, Ferrans VJ, Travis WD.
Immunohistochemical study of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in pulmonary lymphangioleiomyomatosis (LAM).
Hum. Pathol. 28: 1071-8, 1997.
91)  Hayashi T, Rush WL, Travis WD, Liotta LA, Stetler-Stevenson WG, Ferrans VJ.
Immunohistochemical study of matrix metalloproteinases and their tissue inhibitors in pulmonary Langerhans" cell granulomatosis.
Arch. Pathol. Lab. Med. 121: 930-7, 1997.
92)  Yu AE, Hewitt RE, Connor EW, Stetler-Stevenson WG.
Matrix metalloproteinases. Novel targets for directed cancer therapy.
Drugs Aging. 11: 229-44, 1997.
93)  Wu AJ, Lafrenie RM, Park C, Apinhasmit W, Chen ZJ, Birkedal-Hansen H, Yamada KM, Stetler-Stevenson WG, Baum BJ.
Modulation of MMP-2 (gelatinase A) and MMP-9 (gelatinase B) by interferon-gamma in a human salivary gland cell line.
J. Cell. Physiol. 171: 117-24, 1997.
94)  Kenagy RD, Hart CE, Stetler-Stevenson WG, Clowes AW.
Primate smooth muscle cell migration from aortic explants is mediated by endogenous platelet-derived growth factor and basic fibroblast growth factor acting through matrix metalloproteinases 2 and 9.
Circulation. 96: 3555-60, 1997.
95)  Walther MM, Kleiner DE, Lubensky IA, Pozzatti R, Nyguen T, Gnarra JR, Hurley K, Venzon D, Linehan WM, Stetler-Stevenson WG.
Progelatinase A mRNA expression in cell lines derived from tumors in patients with metastatic renal cell carcinoma correlates inversely with survival.
Urology. 50: 295-301, 1997.
96)  Oliver GW, Leferson JD, Stetler-Stevenson WG, Kleiner DE.
Quantitative reverse zymography: analysis of picogram amounts of metalloproteinase inhibitors using gelatinase A and B reverse zymograms.
Anal. Biochem. 244: 161-6, 1997.
97)  Powe DG, Brough JL, Carter GI, Bailey EM, Stetler-Stevenson WG, Turner DR, Hewitt RE.
TIMP-3 mRNA expression is regionally increased in moderately and poorly differentiated colorectal adenocarcinoma.
Br. J. Cancer. 75: 1678-83, 1997.
98)  Stetler-Stevenson WG, Corcoran ML.
Tumor angiogenesis: functional similarities with tumor invasion.
EXS. 79: 413-8, 1997.
99)  De Nictolis M, Garbisa S, Lucarini G, Goteri G, Masiero L, Ciavattini A, Garzetti GG, Stetler-Stevenson WG, Fabris G, Biagini G, Prat J.
72-kilodalton type IV collagenase, type IV collagen, and Ki 67 antigen in serous tumors or the ovary: a clinicopathologic, immunohistochemical, and Serological study.
Int. J. Gynecol. Pathol. 15: 102-9, 1996.
100)  Giannelli G, Brassard J, Foti C, Stetler-Stevenson WG, Falk-Marzillier J, Zambonin-Zallone A, Schiraldi O, Quaranta V.
Altered expression of basement membrane proteins and their integrin receptors in lichen planus: possible pathogenetic role of gelatinases A and B.
Lab. Invest. 74: 1091-104, 1996.
101)  Sato H, Takino T, Kinoshita T, Imai K, Okada Y, Stetler Stevenson WG, Seiki M.
Cell surface binding and activation of gelatinase A induced by expression of membrane-type-1-matrix metalloproteinase (MT1-MMP).
FEBS Lett. 385: 238-40, 1996.
102)  Stetler-Stevenson WG.
Dynamics of matrix turnover during pathologic remodeling of the extracellular matrix.
Am. J. Pathol. 148: 1345-50, 1996.
103)  Sawaya RE, Yamamoto M, Gokaslan ZL, Wang SW, Mohanam S, Fuller GN, McCutcheon IE, Stetler-Stevenson WG, Nicolson GL, Rao JS.
Expression and localization of 72 kDa type IV collagenase (MMP-2) in human malignant gliomas in vivo.
Clin. Exp. Metastasis. 14: 35-42, 1996.
104)  Rao JS, Yamamoto M, Mohaman S, Gokaslan ZL, Fuller GN, Stetler-Stevenson WG, Rao VH, Liotta LA, Nicolson GL, Sawaya RE.
Expression and localization of 92 kDa type IV collagenase/gelatinase B (MMP-9) in human gliomas.
Clin. Exp. Metastasis. 14: 12-8, 1996.
105)  Schoedel KE, Greco MA, Stetler-Stevenson WG, Ohori NP, Goswami S, Present D, Steiner GC.
Expression of metalloproteinases and tissue inhibitors of metalloproteinases in giant cell tumor of bone: an immunohistochemical study with clinical correlation.
Hum. Pathol. 27: 1144-8, 1996.
106)  Celerin M, Ray JM, Schisler NJ, Day AW, Stetler-Stevenson WG, Laudenbach DE.
Fungal fimbriae are composed of collagen.
EMBO J. 15: 4445-53, 1996.
107)  Hayashi T, Stetler-Stevenson WG, Fleming MV, Fishback N, Koss MN, Liotta LA, Ferrans VJ, Travis WD.
Immunohistochemical study of metalloproteinases and their tissue inhibitors in the lungs of patients with diffuse alveolar damage and idiopathic pulmonary fibrosis.
Am. J. Pathol. 149: 1241-56, 1996.
108)  Li Z, Li L, Zielke HR, Cheng L, Xiao R, Crow MT, Stetler-Stevenson WG, Froehlich J, Lakatta EG.
Increased expression of 72-kd type IV collagenase (MMP-2) in human aortic atherosclerotic lesions.
Am. J. Pathol. 148: 121-8, 1996.
109)  Schnaper HW, Kopp JB, Poncelet AC, Hubchak SC, Stetler-Stevenson WG, Klotman PE, Kleinman HK.
Increased expression of extracellular matrix proteins and decreased expression of matrix proteases after serial passage of glomerular mesangial cells.
J. Cell. Sci. 109 ( Pt 10): 2521-8, 1996.
110)  Sun Y, Kim H, Parker M, Stetler-Stevenson WG, Colburn NH.
Lack of suppression of tumor cell phenotype by overexpression of TIMP-3 in mouse JB6 tumor cells identification of a transfectant with increased tumorigenicity and invasiveness.
Anticancer Res. 16: 1-7, 1996.
111)  Brooks PC, Strömblad S, Sanders LC, von Schalscha TL, Aimes RT, Stetler-Stevenson WG, Quigley JP, Cheresh DA.
Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3.
Cell. 85: 683-93, 1996.
112)  Stetler-Stevenson WG, Hewitt R, Corcoran M.
Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic.
Semin. Cancer Biol. 7: 147-54, 1996.
113)  Panchenko MV, Stetler-Stevenson WG, Trubetskoy OV, Gacheru SN, Kagan HM.
Metalloproteinase activity secreted by fibrogenic cells in the processing of prolysyl oxidase. Potential role of procollagen C-proteinase.
J. Biol. Chem. 271: 7113-9, 1996.
114)  Corcoran ML, Hewitt RE, Kleiner DE, Stetler-Stevenson WG.
MMP-2: expression, activation and inhibition.
Enzyme Protein. 49: 7-19, 1996.
115)  Yu AE, Hewitt RE, Kleiner DE, Stetler-Stevenson WG.
Molecular regulation of cellular invasion--role of gelatinase A and TIMP-2.
Biochem. Cell Biol. 74: 823-31, 1996.
116)  Guedez L, Lim MS, Stetler-Stevenson WG.
The role of metalloproteinases and their inhibitors in hematological disorders.
Crit Rev Oncog. 7: 205-25, 1996.
117)  Corcoran ML, Emmert-Buck MR, McClanahan JL, Pelina-Parker M, Stetler-Stevenson WG.
TIMP-2 mediates cell surface binding of MMP-2.
Adv. Exp. Med. Biol. 389: 295-304, 1996.
118)  Zafarullah M, Su S, Martel-Pelletier J, DiBattista JA, Costello BG, Stetler-Stevenson WG, Pelletier JP.
Tissue inhibitor of metalloproteinase-2 (TIMP-2) mRNA is constitutively expressed in bovine, human normal, and osteoarthritic articular chondrocytes.
J. Cell. Biochem. 60: 211-7, 1996.
119)  Vadillo-Ortega F, González-Avila G, Furth EE, Lei H, Muschel RJ, Stetler-Stevenson WG, Strauss JF.
92-kd type IV collagenase (matrix metalloproteinase-9) activity in human amniochorion increases with labor.
Am. J. Pathol. 146: 148-56, 1995.
120)  Bergmann U, Tuuttila A, Stetler-Stevenson WG, Tryggvason K.
Autolytic activation of recombinant human 72 kilodalton type IV collagenase.
Biochemistry. 34: 2819-25, 1995.
121)  Emmert-Buck MR, Emonard HP, Corcoran ML, Krutzsch HC, Foidart JM, Stetler-Stevenson WG.
Cell surface binding of TIMP-2 and pro-MMP-2/TIMP-2 complex.
FEBS Lett. 364: 28-32, 1995.
122)  Mohanam S, Wang SW, Rayford A, Yamamoto M, Sawaya R, Nakajima M, Liotta LA, Nicolson GL, Stetler-Stevenson WG, Rao JS.
Expression of tissue inhibitors of metalloproteinases: negative regulators of human glioblastoma invasion in vivo.
Clin. Exp. Metastasis. 13: 57-62, 1995.
123)  Ray JM, Stetler-Stevenson WG.
Gelatinase A activity directly modulates melanoma cell adhesion and spreading.
EMBO J. 14: 908-17, 1995.
124)  Onisto M, Riccio MP, Scannapieco P, Caenazzo C, Griggio L, Spina M, Stetler-Stevenson WG, Garbisa S.
Gelatinase A/TIMP-2 imbalance in lymph-node-positive breast carcinomas, as measured by RT-PCR.
Int. J. Cancer. 63: 621-6, 1995.
125)  Dhawan S, Weeks BS, Soderland C, Schnaper HW, Toro LA, Asthana SP, Hewlett IK, Stetler-Stevenson WG, Yamada SS, Yamada KM.
HIV-1 infection alters monocyte interactions with human microvascular endothelial cells.
J. Immunol. 154: 422-32, 1995.
126)  Kawamata H, Kameyama S, Kawai K, Tanaka Y, Nan L, Barch DH, Stetler-Stevenson WG, Oyasu R.
Marked acceleration of the metastatic phenotype of a rat bladder carcinoma cell line by the expression of human gelatinase A.
Int. J. Cancer. 63: 568-75, 1995.
127)  Casasco A, Casasco M, Reguzzoni M, Calligaro A, Tateo S, Stetler-Stevenson WG, Liotta LA.
Occurrence and distribution of matrix metalloproteinase-2-immunoreactivity in human embryonic tissues.
Eur J Histochem. 39: 31-8, 1995.
128)  Kawamata H, Kawai K, Kameyama S, Johnson MD, Stetler-Stevenson WG, Oyasu R.
Over-expression of tissue inhibitor of matrix metalloproteinases (TIMP1 and TIMP2) suppresses extravasation of pulmonary metastasis of a rat bladder carcinoma.
Int. J. Cancer. 63: 680-7, 1995.
129)  Corcoran ML, Kleiner DE, Stetler-Stevenson WG.
Regulation of matrix metalloproteinases during extracellular matrix turnover.
Adv. Exp. Med. Biol. 385: 151-9; discussion 179-84, 1995.
130)  Corcoran ML, Stetler-Stevenson WG.
Tissue inhibitor of metalloproteinase-2 stimulates fibroblast proliferation via a cAMP-dependent mechanism.
J. Biol. Chem. 270: 13453-9, 1995.
131)  Rosenberg GA, Estrada EY, Dencoff JE, Stetler-Stevenson WG.
Tumor necrosis factor-alpha-induced gelatinase B causes delayed opening of the blood-brain barrier: an expanded therapeutic window.
Brain Res. 703: 151-5, 1995.
132)  Albini A, Fontanini G, Masiello L, Tacchetti C, Bigini D, Luzzi P, Noonan DM, Stetler-Stevenson WG.
Angiogenic potential in vivo by Kaposi"s sarcoma cell-free supernatants and HIV-1 tat product: inhibition of KS-like lesions by tissue inhibitor of metalloproteinase-2.
AIDS. 8: 1237-44, 1994.
133)  Carome MA, Striker LJ, Peten EP, Elliot SJ, Yang CW, Stetler-Stevenson WG, Reponen P, Tryggvason K, Striker GE.
Assessment of 72-kilodalton gelatinase and TIMP-1 gene expression in normal and sclerotic murine glomeruli.
J. Am. Soc. Nephrol. 5: 1391-9, 1994.
134)  Kohn EC, Jacobs W, Kim YS, Alessandro R, Stetler-Stevenson WG, Liotta LA.
Calcium influx modulates expression of matrix metalloproteinase-2 (72-kDa type IV collagenase, gelatinase A).
J. Biol. Chem. 269: 21505-11, 1994.
135)  Liu L, Shack S, Stetler-Stevenson WG, Hudgins WR, Samid D.
Differentiation of cultured human melanoma cells induced by the aromatic fatty acids phenylacetate and phenylbutyrate.
J. Invest. Dermatol. 103: 335-40, 1994.
136)  Corcoran ML, Stetler-Stevenson WG, DeWitt DL, Wahl LM.
Effect of cholera toxin and pertussis toxin on prostaglandin H synthase-2, prostaglandin E2, and matrix metalloproteinase production by human monocytes.
Arch. Biochem. Biophys. 310: 481-8, 1994.
137)  Wucherpfennig AL, Li YP, Stetler-Stevenson WG, Rosenberg AE, Stashenko P.
Expression of 92 kD type IV collagenase/gelatinase B in human osteoclasts.
J. Bone Miner. Res. 9: 549-56, 1994.
138)  Ulisse S, Farina AR, Piersanti D, Tiberio A, Cappabianca L, D'Orazi G, Jannini EA, Malykh O, Stetler-Stevenson WG, D'Armiento M.
Follicle-stimulating hormone increases the expression of tissue inhibitors of metalloproteinases TIMP-1 and TIMP-2 and induces TIMP-1 AP-1 site binding complex(es) in prepubertal rat Sertoli cells.
Endocrinology. 135: 2479-87, 1994.
139)  Ochieng J, Fridman R, Nangia-Makker P, Kleiner DE, Liotta LA, Stetler-Stevenson WG, Raz A.
Galectin-3 is a novel substrate for human matrix metalloproteinases-2 and -9.
Biochemistry. 33: 14109-14, 1994.
140)  Grigioni WF, D'Errico A, Fiorentino M, Baccarini P, Onisto M, Caenazzo C, Stetler-Stevenson WG, Garbisa S, Mancini AM.
Gelatinase A (MMP-2) and its mRNA detected in both neoplastic and stromal cells of tumors with different invasive and metastatic properties.
Diagn. Mol. Pathol. 3: 163-9, 1994.
141)  Polette M, Gilbert N, Stas I, Nawrocki B, Nöel A, Remacle A, Stetler-Stevenson WG, Birembaut P, Foidart M.
Gelatinase A expression and localization in human breast cancers. An in situ hybridization study and immunohistochemical detection using confocal microscopy.
Virchows Arch. 424: 641-5, 1994.
142)  Costello PC, Del Maestro RF, Stetler-Stevenson WG.
Gelatinase A expression in human malignant gliomas.
Ann. N. Y. Acad. Sci. 732: 450-2, 1994.
143)  Höyhtyä M, Fridman R, Komarek D, Porter-Jordan K, Stetler-Stevenson WG, Liotta LA, Liang CM.
Immunohistochemical localization of matrix metalloproteinase 2 and its specific inhibitor TIMP-2 in neoplastic tissues with monoclonal antibodies.
Int. J. Cancer. 56: 500-5, 1994.
144)  Emmert-Buck MR, Roth MJ, Zhuang Z, Campo E, Rozhin J, Sloane BF, Liotta LA, Stetler-Stevenson WG.
Increased gelatinase A (MMP-2) and cathepsin B activity in invasive tumor regions of human colon cancer samples.
Am. J. Pathol. 145: 1285-90, 1994.
145)  Woodhouse E, Hersperger E, Stetler-Stevenson WG, Liotta LA, Shearn A.
Increased type IV collagenase in lgl-induced invasive tumors of Drosophila.
Cell Growth Differ. 5: 151-9, 1994.
146)  Sawaya R, Tofilon PJ, Mohanam S, Ali-Osman F, Liotta LA, Stetler-Stevenson WG, Rao JS.
Induction of tissue-type plasminogen activator and 72-kDa type-IV collagenase by ionizing radiation in rat astrocytes.
Int. J. Cancer. 56: 214-8, 1994.
147)  Benelli R, Adatia R, Ensoli B, Stetler-Stevenson WG, Santi L, Albini A.
Inhibition of AIDS-Kaposi"s sarcoma cell induced endothelial cell invasion by TIMP-2 and a synthetic peptide from the metalloproteinase propeptide: implications for an anti-angiogenic therapy.
Oncol. Res. 6: 251-7, 1994.
148)  Rosenberg GA, Dencoff JE, McGuire PG, Liotta LA, Stetler-Stevenson WG.
Injury-induced 92-kilodalton gelatinase and urokinase expression in rat brain.
Lab. Invest. 71: 417-22, 1994.
149)  Mertz PM, DeWitt DL, Stetler-Stevenson WG, Wahl LM.
Interleukin 10 suppression of monocyte prostaglandin H synthase-2. Mechanism of inhibition of prostaglandin-dependent matrix metalloproteinase production.
J. Biol. Chem. 269: 21322-9, 1994.
150)  Stetler-Stevenson WG.
Progelatinase A activation during tumor cell invasion.
Invasion Metastasis. 14: 259-68, 1994.
151)  Grigioni WF, D'Errico A, Fortunato C, Fiorentino M, Mancini AM, Stetler-Stevenson WG, Sobel ME, Liotta LA, Onisto M, Garbisa S.
Prognosis of gastric carcinoma revealed by interactions between tumor cells and basement membrane.
Mod. Pathol. 7: 220-5, 1994.
152)  Graham CH, Connelly I, MacDougall JR, Kerbel RS, Stetler-Stevenson WG, Lala PK.
Resistance of malignant trophoblast cells to both the anti-proliferative and anti-invasive effects of transforming growth factor-beta.
Exp. Cell Res. 214: 93-9, 1994.
153)  Jares P, Fernandez PL, Blay M, Aiza G, Stetler-Stevenson WG, Cardesa A, Campo E.
TaqI polymorphism of the human tissue inhibitor of metallo-proteinases-2 (Timp2) gene.
Hum. Mol. Genet. 3: 218, 1994.
154)  Ray JM, Stetler-Stevenson WG.
The role of matrix metalloproteases and their inhibitors in tumour invasion, metastasis and angiogenesis.
Eur. Respir. J. 7: 2062-72, 1994.
155)  Ray JM, Stetler-Stevenson WG.
TIMP-2 expression modulates human melanoma cell adhesion and motility.
Ann. N. Y. Acad. Sci. 732: 233-47, 1994.
156)  Monsky WL, Kelly T, Lin CY, Yeh Y, Stetler-Stevenson WG, Mueller SC, Chen WT.
Binding and localization of M(r) 72,000 matrix metalloproteinase at cell surface invadopodia.
Cancer Res. 53: 3159-64, 1993.
157)  Brown PD, Kleiner DE, Unsworth EJ, Stetler-Stevenson WG.
Cellular activation of the 72 kDa type IV procollagenase/TIMP-2 complex.
Kidney Int. 43: 163-70, 1993.
158)  Rao JS, Steck PA, Mohanam S, Stetler-Stevenson WG, Liotta LA, Sawaya R.
Elevated levels of M(r) 92,000 type IV collagenase in human brain tumors.
Cancer Res. 53: 2208-11, 1993.
159)  Mohtai M, Smith RL, Schurman DJ, Tsuji Y, Torti FM, Hutchinson NI, Stetler-Stevenson WG, Goldberg GI.
Expression of 92-kD type IV collagenase/gelatinase (gelatinase B) in osteoarthritic cartilage and its induction in normal human articular cartilage by interleukin 1.
J. Clin. Invest. 92: 179-85, 1993.
160)  Fridman R, Bird RE, Hoyhtya M, Oelkuct M, Komarek D, Liang CM, Berman ML, Liotta LA, Stetler-Stevenson WG, Fuerst TR.
Expression of human recombinant 72 kDa gelatinase and tissue inhibitor of metalloproteinase-2 (TIMP-2): characterization of complex and free enzyme.
Biochem. J. 289 ( Pt 2): 411-6, 1993.
161)  Stetler-Stevenson WG, Liotta LA, Kleiner DE.
Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis.
FASEB J. 7: 1434-41, 1993.
162)  Weeks BS, Klotman ME, Holloway E, Stetler-Stevenson WG, Kleinman HK, Klotman PE.
HIV-1 infection stimulates T cell invasiveness and synthesis of the 92-kDa type IV collagenase.
AIDS Res. Hum. Retroviruses. 9: 513-8, 1993.
163)  Carome MA, Striker LJ, Peten EP, Moore J, Yang CW, Stetler-Stevenson WG, Striker GE.
Human glomeruli express TIMP-1 mRNA and TIMP-2 protein and mRNA.
Am. J. Physiol. 264: F923-9, 1993.
164)  Aznavoorian S, Murphy AN, Stetler-Stevenson WG, Liotta LA.
Molecular aspects of tumor cell invasion and metastasis.
Cancer. 71: 1368-83, 1993.
165)  Onisto M, Garbisa S, Caenazzo C, Freda MP, Di Francesco C, Nitti D, Liotta LA, Stetler-Stevenson WG.
Reverse transcription-polymerase chain reaction phenotyping of metalloproteinases and inhibitors involved in tumor matrix invasion.
Diagn. Mol. Pathol. 2: 74-80, 1993.
166)  Kleiner DE, Tuuttila A, Tryggvason K, Stetler-Stevenson WG.
Stability analysis of latent and active 72-kDa type IV collagenase: the role of tissue inhibitor of metalloproteinases-2 (TIMP-2).
Biochemistry. 32: 1583-92, 1993.
167)  Kleiner DE, Stetler-Stevenson WG.
Structural biochemistry and activation of matrix metalloproteases.
Curr. Opin. Cell Biol. 5: 891-7, 1993.
168)  Seftor RE, Seftor EA, Stetler-Stevenson WG, Hendrix MJ.
The 72 kDa type IV collagenase is modulated via differential expression of alpha v beta 3 and alpha 5 beta 1 integrins during human melanoma cell invasion.
Cancer Res. 53: 3411-5, 1993.
169)  Murphy AN, Unsworth EJ, Stetler-Stevenson WG.
Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation.
J. Cell. Physiol. 157: 351-8, 1993.
170)  Schnaper HW, Grant DS, Stetler-Stevenson WG, Fridman R, D'Orazi G, Murphy AN, Bird RE, Hoythya M, Fuerst TR, French DL.
Type IV collagenase(s) and TIMPs modulate endothelial cell morphogenesis in vitro.
J. Cell. Physiol. 156: 235-46, 1993.
171)  Templeton NS, Rodgers LA, Levy AT, Ting KL, Krutzsch HC, Liotta LA, Stetler-Stevenson WG.
Cloning and characterization of a novel human cDNA that has DNA similarity to the conserved region of the collagenase gene family.
Genomics. 12: 175-6, 1992.
172)  Ohori NP, Yousem SA, Griffin J, Stanis K, Stetler-Stevenson WG, Colby TV, Sonmez-Alpan E.
Comparison of extracellular matrix antigens in subtypes of bronchioloalveolar carcinoma and conventional pulmonary adenocarcinoma. An immunohistochemical study.
Am. J. Surg. Pathol. 16: 675-86, 1992.
173)  Garbisa S, Scagliotti G, Masiero L, Di Francesco C, Caenazzo C, Onisto M, Micela M, Stetler-Stevenson WG, Liotta LA.
Correlation of serum metalloproteinase levels with lung cancer metastasis and response to therapy.
Cancer Res. 52: 4548-9, 1992.
174)  Fridman R, Fuerst TR, Bird RE, Hoyhtya M, Oelkuct M, Kraus S, Komarek D, Liotta LA, Berman ML, Stetler-Stevenson WG.
Domain structure of human 72-kDa gelatinase/type IV collagenase. Characterization of proteolytic activity and identification of the tissue inhibitor of metalloproteinase-2 (TIMP-2) binding regions.
J. Biol. Chem. 267: 15398-405, 1992.
175)  Campo E, Merino MJ, Tavassoli FA, Charonis AS, Stetler-Stevenson WG, Liotta LA.
Evaluation of basement membrane components and the 72 kDa type IV collagenase in serous tumors of the ovary.
Am. J. Surg. Pathol. 16: 500-7, 1992.
176)  Mullen CA, Coale MM, Levy AT, Stetler-Stevenson WG, Liotta LA, Brandt S, Blaese RM.
Fibrosarcoma cells transduced with the IL-6 gene exhibited reduced tumorigenicity, increased immunogenicity, and decreased metastatic potential.
Cancer Res. 52: 6020-4, 1992.
177)  van den Brûle FA, Engel J, Stetler-Stevenson WG, Liu FT, Sobel ME, Castronovo V.
Genes involved in tumor invasion and metastasis are differentially modulated by estradiol and progestin in human breast-cancer cells.
Int. J. Cancer. 52: 653-7, 1992.
178)  Kleiner DE, Unsworth EJ, Krutzsch HC, Stetler-Stevenson WG.
Higher-order complex formation between the 72-kilodalton type IV collagenase and tissue inhibitor of metalloproteinases-2.
Biochemistry. 31: 1665-72, 1992.
179)  Melchiori A, Albini A, Ray JM, Stetler-Stevenson WG.
Inhibition of tumor cell invasion by a highly conserved peptide sequence from the matrix metalloproteinase enzyme prosegment.
Cancer Res. 52: 2353-6, 1992.
180)  Corcoran ML, Stetler-Stevenson WG, Brown PD, Wahl LM.
Interleukin 4 inhibition of prostaglandin E2 synthesis blocks interstitial collagenase and 92-kDa type IV collagenase/gelatinase production by human monocytes.
J. Biol. Chem. 267: 515-9, 1992.
181)  Stetler-Stevenson WG, Liotta LA, Seldin MF.
Linkage analysis demonstrates that the Timp-2 locus is on mouse chromosome 11.
Genomics. 14: 828-9, 1992.
182)  Seftor RE, Seftor EA, Gehlsen KR, Stetler-Stevenson WG, Brown PD, Ruoslahti E, Hendrix MJ.
Role of the alpha v beta 3 integrin in human melanoma cell invasion.
Proc. Natl. Acad. Sci. U.S.A. 89: 1557-61, 1992.
183)  Stetler-Stevenson WG, Liotta LA, Brown PD.
Role of type IV collagenases in human breast cancer.
Cancer Treat. Res. 61: 21-41, 1992.
184)  Poulsom R, Pignatelli M, Stetler-Stevenson WG, Liotta LA, Wright PA, Jeffery RE, Longcroft JM, Rogers L, Stamp GW.
Stromal expression of 72 kda type IV collagenase (MMP-2) and TIMP-2 mRNAs in colorectal neoplasia.
Am. J. Pathol. 141: 389-96, 1992.
185)  Rosenberg GA, Kornfeld M, Estrada E, Kelley RO, Liotta LA, Stetler-Stevenson WG.
TIMP-2 reduces proteolytic opening of blood-brain barrier by type IV collagenase.
Brain Res. 576: 203-7, 1992.
186)  Stetler-Stevenson WG, Krutzsch HC, Liotta LA.
TIMP-2: identification and characterization of a new member of the metalloproteinase inhibitor family.
Matrix Suppl. 1: 299-306, 1992.
187)  Stetler-Stevenson WG, Bersch N, Golde DW.
Tissue inhibitor of metalloproteinase-2 (TIMP-2) has erythroid-potentiating activity.
FEBS Lett. 296: 231-4, 1992.
188)  Emonard HP, Remacle AG, Noël AC, Grimaud JA, Stetler-Stevenson WG, Foidart JM.
Tumor cell surface-associated binding site for the M(r) 72,000 type IV collagenase.
Cancer Res. 52: 5845-8, 1992.
189)  Margulies IM, Höyhtyä M, Evans C, Stracke ML, Liotta LA, Stetler-Stevenson WG.
Urinary type IV collagenase: elevated levels are associated with bladder transitional cell carcinoma.
Cancer Epidemiol. Biomarkers Prev. 1: 467-74, 1992.
190)  D'Errico A, Garbisa S, Liotta LA, Castronovo V, Stetler-Stevenson WG, Grigioni WF.
Augmentation of type IV collagenase, laminin receptor, and Ki67 proliferation antigen associated with human colon, gastric, and breast carcinoma progression.
Mod. Pathol. 4: 239-46, 1991.
191)  Liotta LA, Stetler-Stevenson WG, Steeg PS.
Cancer invasion and metastasis: positive and negative regulatory elements.
Cancer Invest. 9: 543-51, 1991.
192)  Liotta LA, Steeg PS, Stetler-Stevenson WG.
Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation.
Cell. 64: 327-36, 1991.
193)  Sabsay B, Stetler-Stevenson WG, Lechner JH, Veis A.
Domain structure and sequence distribution in dentin phosphophoryn.
Biochem. J. 276 ( Pt 3): 699-707, 1991.
194)  Grigioni WF, Garbisa S, D'Errico A, Baccarini P, Stetler-Stevenson WG, Liotta LA, Mancini AM.
Evaluation of hepatocellular carcinoma aggressiveness by a panel of extracellular matrix antigens.
Am. J. Pathol. 138: 647-54, 1991.
195)  Seftor RE, Seftor EA, Grimes WJ, Liotta LA, Stetler-Stevenson WG, Welch DR, Hendrix MJ.
Human melanoma cell invasion is inhibited in vitro by swainsonine and deoxymannojirimycin with a concomitant decrease in collagenase IV expression.
Melanoma Res. 1: 43-54, 1991.
196)  Templeton NS, Stetler-Stevenson WG.
Identification of a basal promoter for the human Mr 72,000 type IV collagenase gene and enhanced expression in a highly metastatic cell line.
Cancer Res. 51: 6190-3, 1991.
197)  Levy AT, Cioce V, Sobel ME, Garbisa S, Grigioni WF, Liotta LA, Stetler-Stevenson WG.
Increased expression of the Mr 72,000 type IV collagenase in human colonic adenocarcinoma.
Cancer Res. 51: 439-44, 1991.
198)  Stetler-Stevenson WG, Talano JA, Gallagher ME, Krutzsch HC, Liotta LA.
Inhibition of human type IV collagenase by a highly conserved peptide sequence derived from its prosegment.
Am. J. Med. Sci. 302: 163-70, 1991.
199)  Weinberg WC, Brown PD, Stetler-Stevenson WG, Yuspa SH.
Modulation of hair follicle cell proliferation and collagenolytic activity by specific growth factors.
Ann. N. Y. Acad. Sci. 642: 281-90, 1991.
200)  Castronovo V, Stetler-Stevenson WG, Sobel ME, Liotta LA.
Molecular inhibition of cancer cell invasion and metastasis.
Int. Symp. Princess Takamatsu Cancer Res. Fund. 22: 319-37, 1991.
201)  Ailenberg M, Stetler-Stevenson WG, Fritz IB.
Secretion of latent type IV procollagenase and active type IV collagenase by testicular cells in culture.
Biochem. J. 279 ( Pt 1): 75-80, 1991.
202)  Sang QX, Thompson EW, Grant D, Stetler-Stevenson WG, Byers SW.
Soluble laminin and arginine-glycine-aspartic acid containing peptides differentially regulate type IV collagenase messenger RNA, activation, and localization in testicular cell culture.
Biol. Reprod. 45: 387-94, 1991.
203)  Albini A, Melchiori A, Santi L, Liotta LA, Brown PD, Stetler-Stevenson WG.
Tumor cell invasion inhibited by TIMP-2.
J. Natl. Cancer Inst. 83: 775-9, 1991.
204)  Liotta LA, Stetler-Stevenson WG.
Tumor invasion and metastasis: an imbalance of positive and negative regulation.
Cancer Res. 51: 5054s-5059s, 1991.
205)  Templeton NS, Brown PD, Levy AT, Margulies IM, Liotta LA, Stetler-Stevenson WG.
Cloning and characterization of human tumor cell interstitial collagenase.
Cancer Res. 50: 5431-7, 1990.
206)  Wacher MP, Krutzsch HC, Liotta LA, Stetler-Stevenson WG.
Development of a novel substrate capture immunoassay for the detection of a neutral metalloproteinase capable of degrading basement membrane (type IV) collagen.
J. Immunol. Methods. 126: 239-45, 1990.
207)  Zucker S, Moll UM, Lysik RM, DiMassimo EI, Stetler-Stevenson WG, Liotta LA, Schwedes JW.
Extraction of type-IV collagenase/gelatinase from plasma membranes of human cancer cells.
Int. J. Cancer. 45: 1137-42, 1990.
208)  Weinberg WC, Brown PD, Stetler-Stevenson WG, Yuspa SH.
Growth factors specifically alter hair follicle cell proliferation and collagenolytic activity alone or in combination.
Differentiation. 45: 168-78, 1990.
209)  Sang QX, Stetler-Stevenson WG, Liotta LA, Byers SW.
Identification of type IV collagenase in rat testicular cell culture: influence of peritubular-Sertoli cell interactions.
Biol. Reprod. 43: 956-64, 1990.
210)  Monteagudo C, Merino MJ, San-Juan J, Liotta LA, Stetler-Stevenson WG.
Immunohistochemical distribution of type IV collagenase in normal, benign, and malignant breast tissue.
Am. J. Pathol. 136: 585-92, 1990.
211)  Brown PD, Levy AT, Margulies IM, Liotta LA, Stetler-Stevenson WG.
Independent expression and cellular processing of Mr 72,000 type IV collagenase and interstitial collagenase in human tumorigenic cell lines.
Cancer Res. 50: 6184-91, 1990.
212)  Liotta LA, Stetler-Stevenson WG.
Metalloproteinases and cancer invasion.
Semin. Cancer Biol. 1: 99-106, 1990.
213)  Hendrix MJ, Wood WR, Seftor EA, Lotan D, Nakajima M, Misiorowski RL, Seftor RE, Stetler-Stevenson WG, Bevacqua SJ, Liotta LA.
Retinoic acid inhibition of human melanoma cell invasion through a reconstituted basement membrane and its relation to decreases in the expression of proteolytic enzymes and motility factor receptor.
Cancer Res. 50: 4121-30, 1990.
214)  Stetler-Stevenson WG, Brown PD, Onisto M, Levy AT, Liotta LA.
Tissue inhibitor of metalloproteinases-2 (TIMP-2) mRNA expression in tumor cell lines and human tumor tissues.
J. Biol. Chem. 265: 13933-8, 1990.
215)  Stetler-Stevenson WG.
Type IV collagenases in tumor invasion and metastasis.
Cancer Metastasis Rev. 9: 289-303, 1990.
216)  Stetler-Stevenson WG, Krutzsch HC, Wacher MP, Margulies IM, Liotta LA.
The activation of human type IV collagenase proenzyme. Sequence identification of the major conversion product following organomercurial activation.
J. Biol. Chem. 264: 1353-6, 1989.
217)  Stetler-Stevenson WG, Krutzsch HC, Liotta LA.
Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family.
J. Biol. Chem. 264: 17374-8, 1989.
218)  Stetler-Stevenson WG, Veis A.
Bovine dentin phosphophoryn: calcium ion binding properties of a high molecular weight preparation.
Calcif. Tissue Int. 40: 97-102, 1987.
219)  Stetler-Stevenson WG, Veis A.
Type I collagen shows a specific binding affinity for bovine dentin phosphophoryn.
Calcif. Tissue Int. 38: 135-41, 1986.
220)  Stetler-Stevenson WG, Veis A.
Bovine dentin phosphophoryn: composition and molecular weight.
Biochemistry. 22: 4326-35, 1983.
Click Here to View Collapsed Bibliography.

This page was last updated on 7/2/2014.